文献速递类风湿关节炎脊柱关节炎

炎症性关节病及改善病情抗风湿药患者的流感结局与COVID-19结局比较

Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
PubMed 文献 · Ann Rheum Dis · 2021-11-22

该瑞典全国性队列研究随访116 989例炎症性关节病(IJD)患者及匹配人群对照共四个流感季(2015-2019),发现IJD患者流感住院粗HR 2.38(95%CI 2.21-2.56),校正合并症后降至1.44(95%CI 1.33-1.56);流感死亡粗HR 2.63(95%CI 1.93-3.58),校正后1.46(95%CI 1.07-2.01)。流感绝对风险约为COVID-19的住院一半、死亡十分之一,但IJD与一般人群的相对风险估计相似。

要点

  • IJD患者每季流感住院平均风险0.25%,一般人群0.1%,校正合并症后HR 1.44。
  • IJD患者每季流感死亡平均风险0.015%,一般人群0.006%,校正合并症后HR 1.46。
  • bDMARDs/tsDMARDs似乎不增加季节性流感住院或死亡风险。

核心结论

  • 绝对数上IJD患者COVID-19超过平均季节性流感,但IJD对两种感染的住院和死亡风险均增加50%-100%,且很大程度上取决于相关合并症。
  • 总体上bDMARDs/tsDMARDs似乎不增加季节性流感相关住院或死亡风险。

研究设计与样本

  • 瑞典全国性登记队列研究,随访116 989例IJD患者及匹配人群对照,覆盖2015-2019年四个流感季。
  • 另识别71 556例在每个流感季开始时正使用传统合成DMARDs和bDMARDs/tsDMARDs的IJD患者,通过Cox回归比较不同DMARDs间结局风险。

主要发现

  • 每季流感住院平均风险IJD 0.25% vs 一般人群0.1%,粗HR 2.38(95%CI 2.21-2.56),校正合并症后HR 1.44(95%CI 1.33-1.56)。
  • 每季流感死亡平均风险IJD 0.015% vs 一般人群0.006%,粗HR 2.63(95%CI 1.93-3.58),校正合并症后HR 1.46(95%CI 1.07-2.01)。
  • 流感结局绝对风险为COVID-19的住院一半、死亡十分之一,但IJD与一般人群的相对估计相似。

关键数值与推荐

  • IJD患者每季流感住院平均风险0.25%,一般人群0.1%,粗HR 2.38(95%CI 2.21-2.56),校正合并症后HR 1.44(95%CI 1.33-1.56)。
  • IJD患者每季流感死亡平均风险0.015%,一般人群0.006%,粗HR 2.63(95%CI 1.93-3.58),校正合并症后HR 1.46(95%CI 1.07-2.01)。
  • 流感住院绝对风险为COVID-19的一半,死亡绝对风险为COVID-19的十分之一。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate absolute and relative risks for seasonal influenza outcomes in patients with inflammatory joint diseases (IJDs) and disease-modifying antirheumatic drugs (DMARDs). To contextualise recent findings on corresponding COVID-19 risks. METHODS: Using Swedish nationwide registers for this cohort study, we followed 116 989 patients with IJD and matched population comparators across four influenza seasons (2015-2019). We quantified absolute risks of hospitalisation and death due to influenza, and compared IJD to comparators via Cox regression. We identified 71 556 patients with IJD on active treatment with conventional synthetic DMARDs and biological disease-modifying antirheumatic drugs (bDMARDs)/targeted synthetic disease-modifying antirheumatic drug (tsDMARDs) at the start of each influenza season, estimated risks for the same outcomes and compared these risks across DMARDs via Cox regression. RESULTS: Per season, average risks for hospitalisation listing influenza were 0.25% in IJD and 0.1% in the general population, corresponding to a crude HR of 2.38 (95% CI 2.21 to 2.56) that decreased to 1.44 (95% CI 1.33 to 1.56) following adjustments for comorbidities. For death listing influenza, the corresponding numbers were 0.015% and 0.006% (HR=2.63, 95% CI 1.93 to 3.58, and HR=1.46, 95% CI 1.07 to 2.01). Absolute risks for influenza outcomes were half (hospitalisation) and one-tenth (death) of those for COVID-19, but relative estimates comparing IJD to the general population were similar. CONCLUSIONS: In absolute terms, COVID-19 in IJD outnumbers that of average seasonal influenza, but IJD entails a 50%-100% increase in risk for hospitalisation and death for both types of infections, which is largely dependent on associated comorbidities. Overall, bDMARDs/tsDMARDs do not seem to confer additional risk for hospitalisation or death related to seasonal influenza.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Bower H, Frisell T, Di Giuseppe D, et al. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Ann Rheum Dis. 2021. PMID: 34810197. doi:10.1136/annrheumdis-2021-221461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。